VCEL Earnings Prediction
The chart below shows how VCEL performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VCEL sees a +5.52% change in stock price 10 days leading up to the earnings, and a +0.58% change 10 days following the report. On the earnings day itself, the stock moves by -3.73%. This data can give you a slight idea of what to expect for the next quarter's release.
VCEL Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
75.38M
15.97%
30.17%
Gross Margin
77.61%
3.99%
7.90%
Operating Margin
24.52%
25.17%
-675.59%
Net Margin
26.28%
31.47%
-1784.62%
EPS
0.33
22.22%
-1750.00%
No Data Available
VCEL Earnings Analysis
Vericel Corp Corporation (VCEL.O) Earnings Conference Call
Positive
Exceptional Financial Performance: The company delivered outstanding financial and business results in 2024, generating top tier revenue growth and even higher profitability growth, along with significant operating cash flow.
Strong Revenue Growth: Total revenue was more than $237 million, achieving 20% total revenue growth, with both MACI and Burn Care franchises also growing by 20% or more.
Financial Performance Improvement: Adjusted EBITDA increased to over $50 million, and operating cash flow increased to nearly $60 million, demonstrating strong financial health.
Strong Quarterly Revenue Performance: Record quarterly revenue of over $75 million in Q4, with a gross margin of 78% and an adjusted EBITDA margin of 40%.
Q4 Revenue Growth: MACI revenue for Q4 was more than $68 million, representing 21% growth year-over-year and 53% sequential growth, driven by strong underlying fundamentals.
Sales Rep Productivity Surge: Sales rep productivity for MACI increased significantly to $2.6 million per rep in 2024, indicating effective commercial execution.
Burn Care Revenue Surge: Burn Care revenue increased 22% to approximately $40 million for the year, with strong demand for Epicel and NexoBrid.
Hospital Orders Surge: NexoBrid saw a 42% increase in hospital orders in Q4, indicating strengthening demand and adoption.
GAAP Profitability Achievement: The company achieved GAAP profitability for the year with net income of $10.4 million, a significant improvement from a net loss in 2023.
EBITDA Growth and Profitability: Non-GAAP adjusted EBITDA for the year grew 58% to $53.4 million, demonstrating strong P&L leverage and profitability profile.
Strong Cash Position: The company ended the year with approximately $167 million in cash and no debt, reflecting strong cash generation despite significant CapEx investments.
2025 Revenue and Profit Growth: Guidance for 2025 includes revenue growth of 20% to 23%, with continued margin expansion and profitability growth expected.
MACI Arthro Launch Success: The MACI Arthro launch is showing significant interest, with positive feedback from trained surgeons and strong early performance indicators.
NexoBrid Adoption Growth: NexoBrid's adoption is expected to continue growing, supported by a larger sales force and consistent hospital orders.
Global Market Expansion Potential: The new commercial manufacturing facility is complete, allowing for potential expansion into global markets and increased production capacity.
Negative
Epicel Revenue Decline: Epicel revenue was below recent run rates due to a lower number of patient treatments as a result of patient health issues and fewer graphs per patient.
Rising Operating Expenses: Operating expenses for the year increased to $167.6 million compared to $142 million in 2023, indicating rising costs that could impact profitability.
Operating Expenses Outlook: The company expects full-year operating expenses to be approximately $195 million, which includes $10 million of incremental depreciation and other building-related expenses, suggesting increased financial burden going forward.
Burn Care Revenue Challenges: For Burn Care, although Epicel biopsies in the first quarter currently are ahead of recent quarterly trends, patient treatments and graft per patient continue to be at the lower end of our typical range, mainly due to patient health issues, indicating potential challenges in revenue generation.
Burn Care Revenue Guidance: The guidance for Burn Care revenue is expected to be in the $7 million to $8 million range for the first quarter, which may reflect slower growth compared to previous expectations.
VCEL FAQs
How does VCEL typically perform around its earnings report dates?
Is Vericel Corp (VCEL) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VCEL Earning Call Sentiment
Vericel Corporation (VCEL) Q4 2024 Earnings Conference Call Transcript
VCEL.O
-3.47%Positive
The company reported strong financial performance with record revenue growth and improved profitability, including a significant increase in net income and adjusted EBITDA. Despite some regulatory and competitive pressures, the guidance remains strong, and the company is expanding its product portfolio and market reach. The lack of a share repurchase program is a minor negative, but overall, the financial health and growth prospects are robust, suggesting a positive stock price movement.
